Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients. But as phase 3 results in COPD loom, helmsman Len Schleifer warns that tapping into ...

Dupixent (dupilumab) is a prescription drug. It’s used to treat chronic (ongoing) rhinosinusitis (nasal and sinus inflammation) due to nasal polyps. Dupixent is a biologic drug and does not come in a ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Most people with atopic dermatitis (a type of eczema) are able to control their symptoms by using topical treatments that are applied to the skin. But for some people with severe atopic dermatitis, ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...